【报告导读】1.医药行业持续调整,医保控费导致业绩承压。2.医药行业盈利能力和运营质量位于底部区间。3.创新药行业扭亏加速,多重利好驱动价值回归。4.医药行业表现弱于沪深300。核心观点医药行业持续调整,医保控费导致业绩承压。2024年全年医药行业上市公司营业收入增长0.4%,增速较去年下降4.5pct;归母净利润和扣非归母净利润分别下降8.3%和7.3%,去年分别增长1.0%和2.6%。全年行业...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.